Summarize this content to 2000 words in 6 paragraphs in Arabic Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.GSK will use technologies including artificial intelligence to improve its productivity as a means of compensating for the potential financial hit from US tariffs on the pharmaceutical sector. The UK-listed drugmaker said it was \u201cwell positioned\u201d to respond if the Trump administration decided to hit the industry with tariffs following a probe into the national security implications of pharma imports.\u00a0 GSK has identified \u201cproductivity initiatives\u201d that could save money, such as using technology to improve procurement processes and AI to find efficiencies, according to a person familiar with the matter. The company has also identified \u201cmitigation options\u201d in its supply chain, which could include dual sourcing of ingredients, as well as increased manufacturing in the US, the company said on Wednesday, as it reported first-quarter results.GSK is planning tens of billions of dollars of investment in manufacturing and research and development in the US over the next five years, which is included in its outlooks, it said. GSK already has six manufacturing sites in the US, including an $800mn investment under construction in Pennsylvania which was announced last year. Its comments come after AstraZeneca said on Tuesday it would deepen its manufacturing presence in the US.The pharmaceutical industry was excluded from the so-called reciprocal tariffs announced at the start of April, but US President Donald Trump has repeatedly said he plans to apply them to the sector, in order to encourage investment in US manufacturing. In the first quarter, GSK\u2019s strong sales of speciality medicines compensated for a drop in vaccine sales, helping the pharmaceutical company beat expectations.\u00a0Emma Walmsley, GSK\u2019s chief executive, said speciality medicines, the group\u2019s largest business, delivered \u201cstrong sales\u201d in the quarter, adding that it is focused on upcoming launches of cancer and asthma drugs.\u00a0\u201cThis momentum, together with the strength of our portfolio and proven ability to drive operating leverage, underpin our confidence in guidance for the year and our longer-term outlooks,\u201d she said.\u00a0Total revenue was \u00a37.5bn in the quarter, higher than the consensus forecast for \u00a37.4bn, and up 4 per cent year on year at constant exchange rates.Sales of speciality medicines rose 17 per cent from the same period the year before, but sales of vaccines fell 6 per cent. Sales of Arexvy, the jab for respiratory syncytial virus, fell 57 per cent, after a US advisory body recommended a smaller group of people receive the vaccine. \u00a0Core earnings per share stood at 44.9p, above the average analyst estimate of 40p, and up 5 per cent from the same period the year before.\u00a0Shares in GSK have fallen 12 per cent in the past year. Last quarter, GSK launched a rare \u00a32bn share buyback programme, and on Wednesday, said it had bought back \u00a3273mn in stock so far. It declared a dividend of 16p for the first quarter, and expects to pay a dividend of 64p for the full year.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"
Summarize this content to 2000 words in 6 paragraphs in Arabic Unlock the Editor\u2019s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.GSK will use technologies including artificial intelligence to improve its productivity as a means of compensating for the potential financial hit from US tariffs on the<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[63],"tags":[],"class_list":{"0":"post-296092","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-tech"},"_links":{"self":[{"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/posts\/296092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/comments?post=296092"}],"version-history":[{"count":0,"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/posts\/296092\/revisions"}],"wp:attachment":[{"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/media?parent=296092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/categories?post=296092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globetimeline.com\/ar\/wp-json\/wp\/v2\/tags?post=296092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}